Literature DB >> 9576639

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

N R Cutler1, R J Polinsky, J J Sramek, A Enz, S S Jhee, L Mancione, J Hourani, P Zolnouni.   

Abstract

INTRODUCTION: This study evaluates the activity of SDZ ENA 713, a centrally-selective acetylcholinesterase (AChE) inhibitor, in the cerebral spinal fluid (CSF) of patients with Alzheimer's disease (AD), and its relationship to central and peripheral pharmacokinetic parameters.
METHODS: Eighteen AD patients were enrolled in this open-label, multiple-dose study. Patients were titrated in 1 mg bid/week increments to target doses of 1, 2, 3, 4, 5, or 6 mg bid SDZ ENA 713. After patients had been maintained at their target dose for at least 3 days, continuous CSF samples were obtained via a lumbar catheter for 12.5 h, beginning 0.5 h prior to the final dose of SDZ ENA 713.
RESULTS: Dose-dependent inhibition of CSF AChE was significantly correlated (P < 0.05) with plasma drug and metabolite concentrations. The 6 mg bid treatment group showed a maximum mean inhibition of 62% at 5.6 h post-dose.
CONCLUSION: Rapid, sustained, dose-dependent inhibition of CSF AChE suggests that SDZ ENA 713 has therapeutic potential in AD patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576639     DOI: 10.1111/j.1600-0404.1998.tb00645.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  29 in total

Review 1.  Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

Authors:  Carl H Sadowsky; Joseph L Micca; George T Grossberg; Drew M Velting
Journal:  Prim Care Companion CNS Disord       Date:  2014-09-04

2.  Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression.

Authors:  S Sener; M Ozsarac
Journal:  Emerg Med J       Date:  2006-01       Impact factor: 2.740

Review 3.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

4.  Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.

Authors:  Timothy M Morgan; Bob Soh
Journal:  Br J Clin Pharmacol       Date:  2016-10-26       Impact factor: 4.335

Review 5.  Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

Authors:  B P Imbimbo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Rivastigmine for Alzheimer's disease.

Authors:  Jacqueline S Birks; Lee Yee Chong; John Grimley Evans
Journal:  Cochrane Database Syst Rev       Date:  2015-09-22

Review 7.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Skinfold thickness for rivastigmine patch application in Alzheimer's disease.

Authors:  Ping-Song Chou; Kai-Ming Jhang; Ling-Chun Huang; Wen-Fu Wang; Yuan-Han Yang
Journal:  Psychopharmacology (Berl)       Date:  2019-01-15       Impact factor: 4.530

Review 9.  Rivastigmine. A review of its use in Alzheimer's disease.

Authors:  C M Spencer; S Noble
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 10.  Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

Authors:  A Kurz; M Farlow; G Lefèvre
Journal:  Int J Clin Pract       Date:  2009-05       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.